Metrics as of 10/15/2026, 09:58 AM (Berlin time), refresh in progress.
Contineum Therapeutics Stock
Contineum Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Carmine N. Stengone
- Employees
- 51
- Market cap
- $266 M
- IPO
- 04/04/2024
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the…
Contineum Therapeutics stock: price history
1D
-10.4%
1W
-47.1%
1M
-48.5%
6M
-47.7%
YTD
-38.1%
1Y
-43.2%
2Y
-57.3%
5Y
–
10Y
–
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~10% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Contineum Therapeutics
Analyst assessment of Contineum Therapeutics
PRICE TARGET LOW
US$17.00
CONSENSUS
US$21.33
MEDIAN
US$19.00
PRICE TARGET HIGH
US$28.00
0
STRONG BUY
2
BUY
2
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 15/10/2026
Contineum Therapeutics stock metrics
P/E
-4.09
P/B
1.11
EV/EBITDA
-4.52
RETURN ON EQUITY
-6.3%
NET MARGIN
0.0%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
73.6%
FLOAT SHARES
27,703,073
AVG. DAILY VOLUME (30D)
1,069,750
Insider transactions (SEC)
Stengone Carmine N.
Stengone Carmine N.
Stengone Carmine N.
Stengone Carmine N.
Lorrain Daniel S.
Institutional holders
Comparable stocks
Frequently asked questions about Contineum Therapeutics stock
What does Contineum Therapeutics do?
Contineum Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Carmine N. Stengone, the company employs around 51 people.
The IPO was on 04/04/2024; the stock trades on NASDAQ under the ticker CTNM.
What do analysts say about Contineum Therapeutics stock?
4 analysts rate the stock, the consensus is Buy (as of 15/10/2026).
The average price target is US$21.33, ranging from US$17.00 to US$28.00, with a median of US$19.00.
This is an external assessment, not a statement by Market Jury.
When does Contineum Therapeutics report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly -10% stronger than usual.
Does Contineum Therapeutics pay a dividend?
No, Contineum Therapeutics currently does not pay a dividend.
Which stocks are comparable to Contineum Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Contineum Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Contineum Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.